¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-23   

µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ

ÃâÒßѧÊÔÌâ ICwhqH&  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ! m)P*Lw  
1. Fas(CD95)/FasL R L&z\S  
2. common chain of cytokine receptor \W $bOp  
3 . TCR/CD3 complex =@$G3DM  
4. negaive selection of thymocytes p"" #Gbwj  
5. artificial active immune v3SH+E j4  
6. anti-idiotypic D5x }V  
7. IgSF v ).V&":  
8. Integrin pJ kaP  
9. chemokine C;7?TZ&xw  
10. B7/CD28 &Ohm]g8{2  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© )QS4Z{)U  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ AY{#!RtV  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 ? ->:,I=<~  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ J!r,ktO^U?  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½ *{/ ww9fT  
wBlfQ w-N  
1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ \z>Re$:  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ *K#7,*Oz  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ? tre)  
1. B7/CD28 6b1f ?0  
2. Th1 subset <s/n8#i=H  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© g3[Zh=+]E  
4. antibody affinity maturation U^jxKBq^  
5. AP-1 qFEGV+  
6. single chain variable fragment£¨ScFv£© D5]4(]k&  
7. NK cell receptor S |S N3)  
8. Zinkernagel-Doherty phenomenon Kjbt1n  
9. Ig fold ="E^9!  
10. CD40/CD40L cI} qMc  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© 4.]xK2sW  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ m\a_0!K  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ,#=ykg*~/  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ !e~Yp0gX#  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ {v&c5B~,\  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ D(3\m)  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 8#%Sq=/+M  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ zJ;K4)"j  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 97"dOi!Wh  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© gucd]VH  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© u`E24~  
1.Co-stimulators (or co-stimulating molecules) BcJ]bIbKb  
2.NK-kB 3{e7j6u\  
3.Immunoglobulin superfamily (qn ;MN6<  
4.antigen-presenting cell (APC) o m3$=  
5.death domain =n $@  
6.CCR and CXCR `x;8,7W;B  
7.Lectin (or mitogen) @8zp(1.  
8.Clusters of differentiation, CD) f.f5f%lO~  
9.B7 family GKPC9;{W  
10.Cytotoxic T lymphocyte, CTL) e_C9VNP  
11.IL-15 and IL-15 receptor (IL-15R) 0,)Ao8  
12.MHC restriction J &,N1B  
13.Affinity-chromatography e|wH5(V  
14.Cyctosprin A, CsA Dd+ f,$  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) wg6![Uh  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© u rGk_.f  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 z`gdE0@;d3  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ StUiL>9T#  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 {"33 .^=  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© by*>w/@9)k  
ÃâÒßѧרҵ£º x?Wt\<|h!  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ COS(pfC  
Ïû»¯ÄÚ¿Æ£º >:l; W4j  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ j7;v'eA`;7  
ѪҺ²¡Ñ§×¨Òµ£º 'BT}'qN  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ G?-27Jk8  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 8kZ ~  
(רҵ»ù´¡: ÃâÒßѧ) j=v1:E  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) o l 67x  
1. ADCC(antibody dependent cell-mediated cytotoxicity) < 4DWH  
2. »·æß¾úËØ(cyclosporin) 7e&R6j  
3. KIR(killer cell inhibitory receptor) 9IL#\:d1  
4. HLDA(human leucocyte differentiation antigen) iKB8V<[\T  
5. Interleukin 18(IL-18) LV:oNK(  
6. ÕûºÏËØ(integrin) t1HUp dHY  
7. Fas/FasL 8$avPD3jx  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) SdUtAC2  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) ZTG*|  
10. Th1/Th2 +3e(psdg  
11. »ùÒòÒßÃç(DNAÒßÃç) [KkLpZG  
12. chemokines and chemokine receptor Egt;Bj#%  
13. ÃâÒßÄÍÊÜ |u)?h] >  
14. ¹²´Ì¼¤·Ö×Ó LGT\1u  
15. ËÀÍö½á¹¹Óò(death domain) <FH3 ePz  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 5VWXUNe@_q  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? z Q NL){  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠrWbu oG+8  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î ,_`\c7@  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ gcr,?rE<  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå sSOI5W3A  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 9>psQ0IRvr  
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ GFvZdP`s4  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) '6{q;Bxo  
ÎÊ´ðÌâ(ÿÌâ25·Ö) cWgiFv  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ kgK7 T  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ v:CYf_  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ cl2@p@av  
4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»